These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148 [TBL] [Abstract][Full Text] [Related]
5. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
7. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Campbell KR; Ohman EM; Cantor W; Lincoff AM Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. Pancioli AM; Brott TG CNS Drugs; 2004; 18(14):981-8. PubMed ID: 15584768 [TBL] [Abstract][Full Text] [Related]
10. Therapy for early reperfusion after stroke. Juttler E; Kohrmann M; Schellinger PD Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):656-63. PubMed ID: 17122798 [TBL] [Abstract][Full Text] [Related]
11. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study]. Franzosi MG Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828 [No Abstract] [Full Text] [Related]
12. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Califf RM Am Heart J; 2000 Feb; 139(2 Pt 2):S33-7. PubMed ID: 10650314 [TBL] [Abstract][Full Text] [Related]
13. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Verstraete M Circulation; 2000 Feb; 101(6):E76-80. PubMed ID: 10673265 [TBL] [Abstract][Full Text] [Related]
14. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
15. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Nannizzi-Alaimo L; Alves VL; Phillips DR Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy of intravenous glycoprotein IIB/IIIA inhibitors and tissue plasminogen activator for acute ischemic stroke. Dubey D; Banerjee C; Sawhney A; Sharma A; Alberts MJ Neurol India; 2014; 62(6):631-4. PubMed ID: 25591675 [TBL] [Abstract][Full Text] [Related]
20. Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology. Rossi ML; Zavalloni D Mini Rev Med Chem; 2004 Sep; 4(7):703-9. PubMed ID: 15379638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]